Resumo Fundamento A estimulação ventricular direita convencional aumenta o risco de fibrilação atrial e insuficiência cardíaca em portadores de marca-passo. A estimulação do ramo esquerdo (RE) do sistema His-Purkinje pode evitar os desfechos indesejados da estimulação ventricular direita. Objetivo Analisar retrospectivamente os desfechos intraoperatórios, eletrocardiográficos e os dados clínicos do seguimento inicial de pacientes submetidos à estimulação do RE. Métodos Foram avaliados os parâmetros eletrônicos do implante e eventuais complicações precoces de 52 pacientes consecutivos submetidos à estimulação do sistema de condução. O nível de significância alfa adotado foi igual a 0,05. Resultados 52 pacientes foram submetidos a estimulação do RE do sistema His-Purkinje, obtendo sucesso em 50 procedimentos. 69,2% dos pacientes eram do sexo masculino e a mediana e intervalo interquatil da idade no momento do implante foi de 73,5 (65,0-80,0) anos. A duração do QRS pré-implante foi de 146 (104-175) ms e de 120 (112-130) ms após o procedimento. O tempo de ativação do ventrículo esquerdo foi de 78 (70-84) ms. A amplitude da onda R foi de 12,00 (7,95-15,30) mV, com limiar de estimulação de 0,5 (0,4-0,7) V × 0,4 ms e impedância de 676 (534-780) ohms. O tempo de procedimento foi de 116 (90-130) min e o tempo de fluoroscopia foi de 14,2 (10,0-21,6) min. Conclusão A estimulação cardíaca do sistema de condução His-Purkinje por meio da estimulação do ramo esquerdo é uma técnica segura e factível. Nesta casuística, apresentou alta taxa de sucesso, foi realizada com tempo de procedimento e fluoroscopia baixos e obteve medidas eletrônicas adequadas.

BACKGROUND: Barrett’s esophagus (BE) is a premalignant condition that raises controversy among general practitioners and specialists, especially regarding its diagnosis, treatment, and follow-up protocols. OBJECTIVE: This systematic review aims to present the particularities and to clarify controversies related to the diagnosis, treatment and surveillance of BE. METHODS: A systematic review was conducted on PubMed, Cochrane, and SciELO based on articles published in the last 10 years. PRISMA guidelines were followed and the search was made using MeSH and non-MeSH terms “Barrett” and “diagnosis or treatment or therapy or surveillance”. We searched for complete randomized controlled clinical trials or Phase IV studies, carried out with individuals over 18 years old. RESULTS: A total of 42 randomized controlled trials were selected after applying all inclusion and exclusion criteria. A growing trend of alternative and safer techniques to traditional upper gastrointestinal endoscopy were identified, which could improve the detection of BE and patient acceptance. The use of chromoendoscopy-guided biopsy protocols significantly reduced the number of biopsies required to maintain similar BE detection rates. Furthermore, the value of BE chemoprophylaxis with esomeprazole and acetylsalicylic acid was relevant, as well as the establishment of protocols for the follow-up and endoscopic surveillance of patients with BE based predominantly on the presence and degree of dysplasia, as well as on the length of the follow-up affected by BE. CONCLUSION: Although further studies regarding the diagnosis, treatment and follow-up of BE are warranted, in light of the best evidence presented in the last decade, there is a trend towards electronic chromoendoscopy-guided biopsies for the diagnosis of BE, while treatment should encompass endoscopic techniques such as radiofrequency ablation. Risks of ablative endoscopic methods should be weighted against those of resective surgery. It is also important to consider lifetime endoscopic follow-up for both short and long term BE patients, with consideration to limitations imposed by a range of comorbidities. Unfortunately, there are no randomized controlled trials that have evaluated which is the best recommendation for BE follow-up and endoscopic surveillance (>1 cm) protocols, however, based on current International Guidelines, it is recommended esophagogastroduodenoscopy (EGD) every 5 years in BE without dysplasia with 1 up to 3 cm of extension; every 3 years in BE without dysplasia with >3 up to 10 cm of extension, every 6 to 12 months in BE with low grade dysplasia and, finally, EGD every 3 months after ablative endoscopic therapy in cases of BE with high grade dysplasia.

Acute aortic dissection (AAD) is an important emergency that should be identified promptly. The classification of AAD follows two different systems: Stanford (which defines lesions as types A, on the ascending aorta, or B, on the descending aorta) and DeBakey, which also accounts for the extension of the aortic dissection. We present a notable case of a 63-year-old male who presented with a history of abrupt abdominal pain radiating to the dorsal region for endovascular treatment. He was oliguric with symmetric pulses in the superior limbs and reduction of pulses in the left lower limbs, with signs of hypoperfusion. Angiotomography evidenced acute abdominal thoracic aortic dissection classified as DeBakey III and Stanford B, extending through the left iliac artery. He was submitted to endovascular correction of the abdominal thoracic aortic dissection, with implantation of two straight Valiant type endoprosthesis (26x200 mm and 38x200 mm), positioned after the emergence of the left subclavian artery and right above the celiac trunk, respectively. There was also implantation of the stent graft Viabahn (5x60 mm) and Assurant stent (7x30 mm) in the left renal artery. After the urgent surgical intervention, the patient has recovered well. He has been checked in outpatient follow-ups for the past three years with preserved renal function (1.5 mg/dl creatinine) and correct positioning of the endoprosthesis (confirmed by CT without contrast). Hypertension and a smoking history are the most important risk factors associated with aortic dissections, and should be considered when evaluating a patient with chest or back pain (typically described as sharp rather than tearing or ripping) in the emergency department. The endovascular approach to descending dissections was introduced in 1999 and has been established as the standard approach to descending dissections of the aorta, because of the excess mortality of the open approach (32% in open surgery and 7% for those managed with endovascular techniques) and low rate of complications. Ten-year survival rates for patients with AAD ranging from 30% to 60% justifies an aggressive follow-up strategy of discharge, with the goal of minimizing aortic wall stress through drugs (such as β blockers) and surveillance to detect progression. Our report shows that an early detection of symptoms coupled with an aggressive and precise endovascular intervention has produced satisfactory clinical, laboratorial and quality-of-life outcomes in an older patient with an extensive type B arterial dissection.

No abstract

No abstract